Fast Market Research

"Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2014" Is Now Available at Fast Market Research

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

 
Repost This

Boston, MA -- (SBWIRE) -- 06/11/2014 -- Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alnylam Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Alnylam Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Alnylam Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Alnylam Pharmaceuticals, Inc.'s pipeline products

Reasons to Get This Report

- Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Companies Mentioned in this Report: Alnylam Pharmaceuticals, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Hyperlipidemia - Pipeline Review, H1 2014
- Hypercholesterolemia - Pipeline Review, H1 2014
- Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review
- Sickle Cell Disease - Pipeline Review, H1 2014
- Irritable Bowel Syndrome - Pipeline Review, H1 2014
- BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2014
- Sucampo Pharmaceuticals, Inc. - Product Pipeline Review - 2014
- Portola Pharmaceuticals, Inc. - Product Pipeline Review - 2014
- Cancer Pain - Pipeline Review, H1 2014